Q3 FY2026 · ended Jul 31, 2026 · Revenue $2.34M, +19.0% YoY · Filed Sep 14, 2026
Pharma-Bio Serv, Inc. (PBSV) files with the SEC under industry code 8742, Services-Management Consulting Services. In Q3 of fiscal 2026, the quarter ended Jul 31, 2026, it reported revenue of $2.3 million and a net loss of $14,219. Free cash flow was $59,502. As of Jul 31, 2026 it held $8.6 million in cash and investments and $0 in total debt.
Revenue
$2.34M
+19.0% vs year-ago quarter
Net income
$-14,219
+93.0% vs year-ago quarter
Operating cash flow
$60,892
-74.3% vs year-ago quarter
Free cash flow
$59,502
-74.6% vs year-ago quarter
EPS
$-0.00
+88.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
22.90M
-0.1% vs year-ago quarter
Net cash
$8.58M
Q3 FY2026
Operating margin
-1.6%
TTM
Company profile
- Industry
- Services-Management Consulting Services (SIC 8742)
- Listed as
- PBSV (OTC)
- Fiscal year ends
- October 31
- Headquarters
- Dorado, PR
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1304161
- Former names
- LAWRENCE CONSULTING GROUP INC (until Feb 28, 2006)
Other Services-Management Consulting Services companies
- Cgi Inc GIB
- Booz Allen Hamilton Holding Corp BAH
- Genpact LTD G
- Fti Consulting, Inc FCN
- Exponent Inc EXPO
- Huron Consulting Group Inc. HURN
- Astrana Health, Inc. ASTH
- ICF International, Inc. ICFI
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Jul 31, 2026 |
Q2 FY2026 Apr 30, 2026 |
Q1 FY2026 Jan 31, 2026 |
Q4 FY2025 Oct 31, 2025 |
Q3 FY2025 Jul 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $2.3M | $2.7M | $2.3M | $2.1M | $2.0M |
| Operating income | -$71,812 | $144,676 | -$94,535 | -$133,272 | -$313,877 |
| Net income | -$14,219 | $232,986 | $32,860 | -$102 | -$204,250 |
| Diluted EPS | -$0.00 | $0.01 | $0.00 | -$0.00 | -$0.01 |
| Operating cash flow | $60,892 | -$365,311 | -$390,139 | $279,666 | $236,524 |
| Free cash flow | $59,502 | -$367,632 | -$392,550 | $279,316 | $234,488 |
| Total assets | $11.4M | $11.5M | $13.5M | $13.7M | $13.6M |
| Total liabilities | $994,740 | $1.0M | $3.3M | $1.7M | $1.7M |
| Stockholders' equity | $10.4M | $10.5M | $10.2M | $11.9M | $11.9M |
| Cash and investments | $8.6M | $8.5M | $10.6M | $10.9M | $10.7M |
| Total debt | $0 | $0 | $0 | $28,834 | $71,362 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Sep 14, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Results of operations
|
Jun 15, 2026 | Jun 15, 2026 |
| 10-Q | Quarterly report | Jun 15, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 15, 2026 | May 15, 2026 |
| ARS | Annual report to shareholders | Apr 16, 2026 | Oct 31, 2025 |
All 527 Pharma-Bio Serv, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.